Clene Inc. Secures $5.67M in Equity and Warrant Offering at Premium to Market, Addressing Going Concern

summarizeSummary

Clene Inc. has raised approximately $5.67 million in net proceeds through a direct offering of common stock and warrants to institutional investors and directors, priced at a premium to the market, to fund clinical development and address its going concern warning.

check_boxKey Events

• Capital Raise

  Clene Inc. secured approximately $5.67 million in net proceeds from a direct offering of 928,333 common shares and warrants to purchase 3,713,333 additional shares.

• Premium Pricing

  The offering was priced at $6.50 per unit, which is above the last reported sale price of $5.97 on January 8, 2026, and today's stock price of $6.395.

• Insider Participation

  Directors of Clene Inc. purchased approximately $325,000 worth of units in the offering, demonstrating internal confidence.

• Addressing Going Concern

  The proceeds are intended to fund clinical development and general corporate purposes, directly addressing the company's previously disclosed 'going concern' warning.

auto_awesomeAnalysis

This offering is a critical financing event for Clene Inc., which has explicitly stated substantial doubt about its ability to continue as a going concern. The company successfully raised approximately $5.67 million in net proceeds, which will be used to fund clinical development of its lead drug candidate, CNM-Au8, and for general corporate purposes. The offering was priced at $6.50 per unit, a premium to the last reported sale price of $5.97 on January 8, 2026, and today's stock price of $6.395, indicating investor confidence despite the company's financial challenges. Notably, certain directors participated in the offering, purchasing approximately $325,000 worth of securities, further signaling internal conviction. While the offering includes warrants that could lead to significant future dilution if exercised, the immediate capital infusion provides a crucial lifeline and extends the company's operational runway. Investors should monitor the company's progress in clinical trials and its ability to secure further non-dilutive funding or achieve regulatory milestones.